Aegerion Pharmaceuticals Inc., a Cambridge, Massachusetts-based subsidiary of Novelion Therapeutics Inc., will plead guilty to charges relating to its prescription drug, Juxtapid. Aegerion introduced Juxtapid into interstate commerce that was misbranded because, among other things, Aegerion failed to comply with a Risk Evaluation and Mitigation Strategy (REMS). The resolution also includes a deferred prosecution agreement relating to criminal liability under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Aegerion will pay more than $35 million to resolve criminal and civil liability arising from these matters.
— source corporatecrimereporter.com | Sep 28th, 2017